With two new uses kaput, AstraZeneca touts more long-term Brilinta data at ESC
admin 24th August 2017 Uncategorised 0AstraZeneca has pegged big hopes on its clot-fighter Brilinta, and it continues to roll out numbers designed to advance them. But with two trial failures last year, and backing for long-term use already sewn up, the company might have better luck elsewhere.
More: With two new uses kaput, AstraZeneca touts more long-term Brilinta data at ESC
Source: fierce